Researchers from Janssen Research & Development LLC presented preclinical data for JNJ-87801493, a first-in-class CD20 targeted CD28 costimulatory bispecific antibody (Ab), currently in early clinical ...

Nectin-4 antibody-drug conjugate (ADC) and checkpoint inhibitor combinations have represented a great advancement in the treatment of bladder cancer, but relapse and treatment-related toxicities ...

It took less than an hour to realize something had gone terribly wrong. In March 2006, six healthy volunteers of a Phase I clinical trial who had received a single infusion of the CD28 ...

The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for ...

Conventionally, the first and second stimulation signals in vitro, simulating the process in vivo, are achieved using anti-CD3 antibody, anti-CD28 antibody, or CD3/CD28 magnetic beads, along with the ...